









Markets
/
Stocks
/
nasdaq-syk
/

Stryker Corp

SYK

377.310USD

-6.030-1.57%

Close 09/15, 16:00（ET）Quotes delayed by 15 min

144.25BMarket Cap

49.43P/E TTM



Stryker Corp

377.310

-6.030-1.57%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-12

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

30 / 207

Overall Ranking

141 / 4724

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 33 analysts

Buy

Current Rating

433.807

Target Price

+13.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Stryker Corporation (Stryker) is a medical technology company. It offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. It operates through two segments: MedSurg and Neurotechnology, and Orthopedics and Spine. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products. It also develops neurointerventional devices for the treatment of intracranial aneurysms. It offers Fortress, a modular wall system for hospitals and ambulatory surgery centers. It specializes in soft tissue fixation products and delivering AI-assisted virtual care workflows.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.47% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 26.93.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 41.30%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 41.30%.

Overvalued

The company’s latest PE is 50.14, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 329.22M shares, decreasing 0.48% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 33.35M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-12

The company's current financial score is 7.37, which is higher than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 5.87B, representing a year-over-year increase of 11.88%, while its net profit experienced a year-over-year increase of 17.01%.

Score

Industry at a Glance

Previous score

7.37

Change



Financials

7.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.91

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.58

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.77

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.38

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-12

The company’s current valuation score is 4.80, which is higher than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 51.43, which is -16.55% below the recent high of 42.91 and 24.32% above the recent low of 38.92.

Score

Industry at a Glance

Previous score

3.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 30/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-12

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Stryker Corp is 438.00, with a high of 485.00 and a low of 315.50.

Score

Industry at a Glance

Previous score

8.06

Change

Support & Resistance

No Data

Analyst Rating

Based on 33 analysts

Buy

Current Rating

433.807

Target Price

+13.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Stryker Corp

SYK

Medtronic PLC

MDT

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

Insulet Corp

PODD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-12

The company’s current price momentum score is 9.04, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 405.99 and the support level at 376.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.98

Change

-0.3

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.345

Neutral

RSI(14)

44.632

Neutral

STOCH(KDJ)(9,3,3)

27.434

Sell

ATR(14)

6.265

High Vlolatility

CCI(14)

-155.097

Sell

Williams %R

88.086

Oversold

TRIX(12,20)

0.046

Sell

StochRSI(14)

11.653

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

388.194

Sell

MA10

389.753

Sell

MA20

389.497

Sell

MA50

389.050

Sell

MA100

384.930

Sell

MA200

380.281

Sell

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 86.11%, representing a quarter-over-quarter decrease of 0.68%. The largest institutional shareholder is The Vanguard, holding a total of 33.35M shares, representing 8.72% of shares outstanding, with 2.16% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

32.91M

+1.11%

Brown (John W)

20.06M

Greenleaf Trust

17.12M

-1.57%

BlackRock Institutional Trust Company, N.A.

16.59M

+0.03%

State Street Global Advisors (US)

14.81M

+0.19%

T. Rowe Price Associates, Inc.

Star Investors

11.62M

+9.53%

Geode Capital Management, L.L.C.

7.31M

+3.40%

JP Morgan Asset Management

7.47M

+9.84%

Capital Research Global Investors

6.86M

+0.33%

Fidelity Management & Research Company LLC

7.19M

-2.43%

Risk Assessment

Currency: USD Updated：2025-09-12

The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.